Physician profile
Yuvaraj Singh
NPI 1992359517
$2,204.97
in general payments reported to CMS, 2019-2025
20 companies · $86.24 in 2025
The $86.24 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $359 · 2021: $367 · 2022: $504 · 2023: $481 · 2024: $207 · 2025: $86.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.78 | 2020-2024 | Avycaz |
| Astrazeneca Pharmaceuticals LP | $378.07 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $239.57 | 2021-2023 | Opdivo, Camzyos |
| Gilead Sciences, INC. | $221.19 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.35 | 2023-2024 | Entyvio |
| Pfizer INC. | $142.68 | 2019-2022 | |
| Alcresta Therapeutics, INC. | $116.18 | 2023 | Relizorb |
| Alexion Pharmaceuticals, INC. | $113.27 | 2019-2023 | |
| Genzyme Corporation | $86.24 | 2025 | |
| Novo Nordisk INC | $84.12 | 2019-2023 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $47.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.53 | 2021 | |
| Karyopharm Therapeutics INC. | $31.91 | 2022 | |
| Boston Scientific Corporation | $27.29 | 2024 | Axios |
| Jazz Pharmaceuticals INC. | $21.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $20.96 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.95 | 2023 | Gvoke Hypopen |
| Fresenius Kabi USA, LLC | $15.83 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.68 | 2021 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuvaraj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.